Gregg Keaney
'05 PhD Synthetic Organic Chemistry // Senior Vice President of CMC (Chemistry, Manufacturing, and Controls) and Product Development at Rapport Therapeutics
Gregg is the Senior Vice President of CMC (Chemistry, Manufacturing, and Controls) and Product Development at Rapport Therapeutics where he develops small molecules to leverage the science of receptor-associated proteins for precision neuromedicines. He received his PhD in Synthetic Organic Chemistry from Yale in '05. Gregg is an entrepreneurial drug hunter who has been one of the early employees at several Boston-area biotech companies with roles spanning across the drug discovery and development spectrum. Gregg has held positions of increasing responsibility at Third Harmonic Bio, Cadent Therapeutics, Ataxion Therapeutics, H3 Biomedicine, and Infinity Pharmaceuticals in the areas of product development, drug substance and drug product manufacturing, and medicinal chemistry in the therapeutic areas of oncology, neuroscience, and allergy. He has a demonstrated track record of building biotech companies from the single-digit stealth stage through beyond IPO.